美泊利珠单抗治疗FIP1样1-血小板衍化生长因子受体α阴性高嗜酸性粒细胞综合征的应用进展  

Advances in the application of mepolizumab in the treatment of FIP1L1-PDGFRα-negative hypereosinophilic syndrome

作　　者：孟静 张学兰 赵健 叶小萌 MENG Jing;ZHANG Xuelan;ZHAO Jian;YE Xiaomeng(Department of Respiratory Medicine,Armed Police Corps Hospital of Anhui Province,Hefei 230041,China)

机构地区：[1]武警安徽省总队医院呼吸内科,合肥230041

出　　处：《临床药物治疗杂志》2024年第7期6-10,共5页Clinical Medication Journal

摘　　要：高嗜酸性粒细胞综合征(HES)是一种以外周血嗜酸性粒细胞持续增高及嗜酸性粒细胞介导的靶器官损害为特征的罕见血液系统疾病,其治疗目标主要是长期降低组织或血液中的嗜酸性粒细胞水平,预防或逆转其对组织器官的损伤。美泊利珠单抗能显著减少HES发作次数,降低组织和血液中嗜酸性粒细胞水平,已被FDA批准用于FIP1样1-血小板衍化生长因子受体α(FIP1L1-PDGFRα)阴性的HES。本文就美泊利珠单抗在FIP1L1-PDGFRα阴性HES治疗中的应用现状进行综述。Hypereosinophilic syndrome(HES)is a rare hematological disease characterized by persistent eosinophilia in the peripheral blood and eosinophil-mediated damage to target organs.The primary goal of treatment is to reduce the longterm levels of eosinophils in tissues or blood,and to prevent or reverse its damage in tissues and organs.Mepolizumab has been shown to significantly decrease the frequency of HES flares and lower eosinophil levels in tissues and blood.It has been approved by the FDA for use in fip1-like 1-platelet-derived growth factor receptor alpha(FIP1L1-PDGFRα)-negative HES.This article reviews the current status of mepolizumab in the treatment of FIP1L1-PDGFRα-negative HES..

关 键 词：美泊利珠单抗 高嗜酸性粒细胞综合征 嗜酸性粒细胞 急性发作 

分 类 号：R979.5[医药卫生—药品] R593.1[医药卫生—药学]